Home › Research › Tau biomarkers
[Biochemical markers for Alzheimer disease]
Czarna JM, Waldemar G, Heegaard NH.. Ugeskrift for laeger, 2006-03-01
Topic: Amyloid, tau and blood-test diagnosis
It is estimated that approximately 40,000 people in Denmark suffer from Alzheimer's disease (AD), a neurodegenerative dementia. Symptomatic treatment now exists which can temporarily inhibit the loss of brain function. Unfortunately, AD is difficult to diagnose, especially early in the disease course, and a definite diagnosis is possible only post-mortem.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Czarna, J. M., Waldemar, G., & Heegaard, N. H. (2006). [Biochemical markers for Alzheimer disease]. Ugeskrift for laeger.
Vancouver
Czarna JM, Waldemar G, Heegaard NH. [Biochemical markers for Alzheimer disease]. Ugeskrift for laeger. 2006. PMID: 16522291.
BibTeX
@article{czarna2006-16522291,
author = {Czarna, J. M. and Waldemar, G. and Heegaard, N. H.},
title = {{[Biochemical markers for Alzheimer disease]}},
journal = {Ugeskrift for laeger},
year = {2006},
pmid = {16522291}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Symptomatic treatment now exists which can temporarily inhibit the loss of brain function.
- Unfortunately, AD is difficult to diagnose, especially early in the disease course, and a definite diagnosis is possible only post-mortem.
- To develop improved diagnostic methods, several biomarkers have been examined for their ability to differentiate AD from normal aging and other dementias.
- Their measurement in blood samples has not yet been developed, but analyses may now be routinely performed using cerebrospinal fluid (CSF).
Why it matters
This paper discusses that Alzheimer's disease is difficult to diagnose early and that a definite diagnosis is only possible post-mortem, while reviewing biomarkers for distinguishing it from normal aging and other dementias. It concerns diagnosis and does not report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants40,000
- Evidence strengthLow
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record and impact for its field and year, so those were left out: it earned 33 of the 90 points we could judge it on, which is 37 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Ugeskrift for laeger) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 4 / 4 | 40,000 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.1 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Niels H. H. Heegaard: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Rigshospitalet: institution h-index 882 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16522291) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 33 / 90 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 33 of the 90 points we could judge it on is 37 out of 100. |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related studies in Tau biomarkers
Also in Tau biomarkers
56 studies in the library are filed under Tau biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Tau biomarkers hub.